Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cigna GroupCI · Entity 550 | Pres, Government and Solutions | November 19, 2021 | November 23, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cigna Group
Report date November 19, 2021 · Filed November 23, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $.01 Par ValueSEC Table I · non-derivative | Direct | 43,488 |
Reported balance
After 2021-11-19 transaction · row 1
1 source rowRow 1 · 2021-11-19 · Tax withholding · Disposed 1,081 · Balance 43,488 F1: Represents shares withheld to satisfy tax obligations upon vesting of restricted shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld to satisfy tax obligations upon vesting of restricted shares.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Cigna Holding Co
Report date December 20, 2018 · Filed December 26, 2018
Section 16 reporting ended · disclosed 2018-12-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $.25 Par ValueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 1
1 source rowRow 1 · 2018-12-20 · Disposition to issuer · Disposed 37,777 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F5: Includes 2,352 restricted shares. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $78.04 · Expires 2024-02-26 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-12-20 · Disposition to issuer · Disposed 39,038 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F3: This option was fully vested and exercisable at the time of the Merger. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $120.90 · Expires 2025-02-25 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-12-20 · Disposition to issuer · Disposed 30,229 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F3: This option was fully vested and exercisable at the time of the Merger. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $139.22 · Expires 2026-03-01 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-12-20 · Disposition to issuer · Disposed 34,035 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F3: This option was fully vested and exercisable at the time of the Merger. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $149.14 · Expires 2027-02-28 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-12-20 · Disposition to issuer · Disposed 28,038 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F3: This option was fully vested and exercisable at the time of the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote)
F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.
F3: This option was fully vested and exercisable at the time of the Merger.
F4: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option.
F5: Includes 2,352 restricted shares.
NeueHealth, Inc.
Report date October 02, 2025 · Filed October 06, 2025
Section 16 reporting ended · disclosed 2025-10-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-10-02 transaction · row 1
1 source rowRow 1 · 2025-10-02 · Disposition to issuer · Disposed 16,741 · Balance 0 F1: On October 2, 2025, NH Holdings 2025, Inc. ("Parent"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and NH Holdings Acquisition 2025, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), dated as of December 23, 2024 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). Parent and Merger Sub are indirectly controlled by private investment funds affiliated with New Enterprise Associates, Inc. F2: Pursuant to the Rollover Agreement, dated as of August 14, 2025 (the "Rollover Agreement"), entered into by and among NH Holdings 2025 SPV, L.P. ("Holdings"), NH Holdings 2025, Inc., NH Holdings Acquisition 2025, Inc. and the Reporting Person, the Reporting Person contributed its shares of Issuer common stock, Series A Convertible Perpetual Preferred Stock ("Series A Preferred Stock") and Series B Convertible Perpetual Preferred Stock ("Series B Preferred Stock") to Holdings in exchange for Holdings common units, series A preferred units and series B preferred units on a one for one basis in accordance with the Rollover Agreement, and effective as of the effective time of the Merger (the "Effective Time"). |
Filing footnotes · ownership attribution and instrument terms
F1: On October 2, 2025, NH Holdings 2025, Inc. ("Parent"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and NH Holdings Acquisition 2025, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), dated as of December 23, 2024 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). Parent and Merger Sub are indirectly controlled by private investment funds affiliated with New Enterprise Associates, Inc.
F2: Pursuant to the Rollover Agreement, dated as of August 14, 2025 (the "Rollover Agreement"), entered into by and among NH Holdings 2025 SPV, L.P. ("Holdings"), NH Holdings 2025, Inc., NH Holdings Acquisition 2025, Inc. and the Reporting Person, the Reporting Person contributed its shares of Issuer common stock, Series A Convertible Perpetual Preferred Stock ("Series A Preferred Stock") and Series B Convertible Perpetual Preferred Stock ("Series B Preferred Stock") to Holdings in exchange for Holdings common units, series A preferred units and series B preferred units on a one for one basis in accordance with the Rollover Agreement, and effective as of the effective time of the Merger (the "Effective Time").
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 02, 2025 Filed Oct 6, 2025 22:15 UTC | NeueHealth, Inc. NEUE · Entity 74308 | Disposition to issuerCommon Stock | 16,741 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-044372 · wk-form4_1759788928.xml · nonDerivative · entry 1 Manders Matthew G · CIK 0001480601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: On October 2, 2025, NH Holdings 2025, Inc. ("Parent"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and NH Holdings Acquisition 2025, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), dated as of December 23, 2024 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). Parent and Merger Sub are indirectly controlled by private investment funds affiliated with New Enterprise Associates, Inc. F2 · price: Pursuant to the Rollover Agreement, dated as of August 14, 2025 (the "Rollover Agreement"), entered into by and among NH Holdings 2025 SPV, L.P. ("Holdings"), NH Holdings 2025, Inc., NH Holdings Acquisition 2025, Inc. and the Reporting Person, the Reporting Person contributed its shares of Issuer common stock, Series A Convertible Perpetual Preferred Stock ("Series A Preferred Stock") and Series B Convertible Perpetual Preferred Stock ("Series B Preferred Stock") to Holdings in exchange for Holdings common units, series A preferred units and series B preferred units on a one for one basis in accordance with the Rollover Agreement, and effective as of the effective time of the Merger (the "Effective Time"). Read SEC document |
| May 13, 2025 Filed May 15, 2025 22:15 UTC | NeueHealth, Inc. NEUE · Entity 74308 | Exercise / conversionRestricted Stock Units · Derivative | 10,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-026084 · wk-form4_1747347313.xml · derivative · entry 2 Manders Matthew G · CIK 0001480601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: All of these restricted stock units vested on May 13, 2025, one year from the grant date. F2 · derivative.expiration_date: All of these restricted stock units vested on May 13, 2025, one year from the grant date. Read SEC document |
| May 13, 2025 Filed May 15, 2025 22:15 UTC | NeueHealth, Inc. NEUE · Entity 74308 | Exercise / conversionCommon Stock | 10,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-026084 · wk-form4_1747347313.xml · nonDerivative · entry 1 Manders Matthew G · CIK 0001480601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,741 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 13, 2024 Filed May 15, 2024 01:09 UTC | NeueHealth, Inc. NEUE · Entity 74308 | GrantRestricted Stock Units · Derivative | 10,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-023357 · wk-form4_1715735353.xml · derivative · entry 3 Manders Matthew G · CIK 0001480601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 10,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: All of these restricted stock units vest on May 13, 2025, one year from the grant date. F3 · derivative.expiration_date: All of these restricted stock units vest on May 13, 2025, one year from the grant date. Read SEC document |
| May 12, 2024 Filed May 15, 2024 01:09 UTC | NeueHealth, Inc. NEUE · Entity 74308 | Exercise / conversionRestricted Stock Units · Derivative | 4,755 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-023357 · wk-form4_1715735353.xml · derivative · entry 2 Manders Matthew G · CIK 0001480601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,755 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: All of these restricted stock units vested on May 12, 2024, one year from the grant date. F2 · derivative.expiration_date: All of these restricted stock units vested on May 12, 2024, one year from the grant date. Read SEC document |
| May 12, 2024 Filed May 15, 2024 01:09 UTC | NeueHealth, Inc. NEUE · Entity 74308 | Exercise / conversionCommon Stock | 4,755 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-023357 · wk-form4_1715735353.xml · nonDerivative · entry 1 Manders Matthew G · CIK 0001480601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,241 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 13, 2023 Filed May 17, 2023 00:20 UTC | NeueHealth, Inc. BHG · Entity 74308 | Exercise / conversionRestricted Stock Units · Derivative | 118,886 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-018526 · wf-form4_168428279652807.xml · derivative · entry 2 Manders Matthew G · CIK 0001480601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 118,886 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: All of the restricted stock units vested on May 13, 2023, one year from the grant date. F2 · derivative.expiration_date: All of the restricted stock units vested on May 13, 2023, one year from the grant date. Read SEC document |
| May 13, 2023 Filed May 17, 2023 00:20 UTC | NeueHealth, Inc. BHG · Entity 74308 | Exercise / conversionCommon Stock | 118,886 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-018526 · wf-form4_168428279652807.xml · nonDerivative · entry 1 Manders Matthew G · CIK 0001480601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,886 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 12, 2023 Filed May 17, 2023 00:20 UTC | NeueHealth, Inc. BHG · Entity 74308 | GrantRestricted Stock Units · Derivative | 380,434 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-018526 · wf-form4_168428279652807.xml · derivative · entry 3 Manders Matthew G · CIK 0001480601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 380,434 Underlying: Common Stock · 380,434 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: All of the restricted stock units vest on May 12, 2024, one year from the grant date. F3 · derivative.expiration_date: All of the restricted stock units vest on May 12, 2024, one year from the grant date. Read SEC document |
| May 13, 2022 Filed May 18, 2022 01:15 UTC | NeueHealth, Inc. BHG · Entity 74308 | GrantRestricted Stock Units · Derivative | 118,886 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-005194 · form4-05172022_060522.xml · derivative · entry 1 Manders Matthew G · CIK 0001480601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,886 Underlying: Common Stock · 118,886 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units vest one year from the date of the grant. F2 · derivative.expiration_date: The restricted stock units vest one year from the date of the grant. Read SEC document |
| November 19, 2021 Filed Nov 23, 2021 23:01 UTC | Cigna Group CI · Entity 550 | Tax withholdingCommon Stock, $.01 Par Value | 1,081 | $213.65 | $230,955.65 |
DisclosureSEC source: 0001225208-21-014116 · doc4.xml · nonDerivative · entry 1 Manders Matthew G · CIK 0001480601 · Pres, Government and Solutions 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,488 F1 · shares: Represents shares withheld to satisfy tax obligations upon vesting of restricted shares. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 01:27 UTC | Cigna Group CI · Entity 550 | SaleCommon Stock, $.01 Par Value | 3,087 | $212.37 | $655,586.19 |
DisclosureSEC source: 0001225208-21-004365 · doc4.xml · nonDerivative · entry 4 Manders Matthew G · CIK 0001480601 · Pres, Government and Solutions 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,569 F4 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2020. Read SEC document |
| February 26, 2021 Filed Mar 3, 2021 01:27 UTC | Cigna Group CI · Entity 550 | Tax withholdingCommon Stock, $.01 Par Value | 2,270 | $210.31 | $477,403.70 |
DisclosureSEC source: 0001225208-21-004365 · doc4.xml · nonDerivative · entry 3 Manders Matthew G · CIK 0001480601 · Pres, Government and Solutions 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,656 F3 · shares: Represents shares withheld to satisfy tax obligations upon settlement of strategic performance shares. Read SEC document |
| February 26, 2021 Filed Mar 3, 2021 01:27 UTC | Cigna Group CI · Entity 550 | Tax withholdingCommon Stock, $.01 Par Value | 1,072 | $210.31 | $225,452.32 |
DisclosureSEC source: 0001225208-21-004365 · doc4.xml · nonDerivative · entry 2 Manders Matthew G · CIK 0001480601 · Pres, Government and Solutions 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,926 F2 · shares: Represents shares withheld to satisfy tax obligations upon vesting of restricted shares. Read SEC document |
| February 26, 2021 Filed Mar 3, 2021 01:27 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 5,357 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-004365 · doc4.xml · nonDerivative · entry 1 Manders Matthew G · CIK 0001480601 · Pres, Government and Solutions 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,998 F1 · shares: The reported securities are shares of common stock received pursuant to the settlement of strategic performance shares for the 2018-2020 three-year performance period. The number of shares of common stock received was based upon actual performance against pre-established Company performance goals. Read SEC document |
| February 24, 2021 Filed Feb 27, 2021 01:22 UTC | Cigna Group CI · Entity 550 | GrantEmployee Stock Option (Right to Buy) · Derivative | 24,884 | $0.00 Strike: $213.80 | $0.00 |
DisclosureSEC source: 0001225208-21-003974 · doc4.xml · derivative · entry 2 Manders Matthew G · CIK 0001480601 · Pres, Government and Solutions 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,884 Underlying: Common Stock, $.01 Par Value · 24,884 shares Expires 2031-02-24 F2 · derivative.exercise_date: This option vests in three equal annual installments beginning March 1, 2022. Read SEC document |
| February 24, 2021 Filed Feb 27, 2021 01:22 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 5,219 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003974 · doc4.xml · nonDerivative · entry 1 Manders Matthew G · CIK 0001480601 · Pres, Government and Solutions 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,641 F1 · shares: These restricted shares vest in three equal annual installments beginning March 1, 2022. Read SEC document |
| January 21, 2021 Filed Jan 25, 2021 23:40 UTC | Cigna Group CI · Entity 550 | SaleCommon Stock, $.01 Par Value | 5,596 | $230.06 | $1,287,438.14 |
DisclosureSEC source: 0001225208-21-001113 · doc4.xml · nonDerivative · entry 1 Manders Matthew G · CIK 0001480601 · Pres, Government and Solutions 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,422 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2020. F2 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $230.00 to $230.14 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 01:46 UTC | Cigna Group CI · Entity 550 | SaleCommon Stock, $.01 Par Value | 3,969 | $182.85 | $725,731.65 |
DisclosureSEC source: 0001225208-20-003954 · doc4.xml · nonDerivative · entry 4 Manders Matthew G · CIK 0001480601 · President, Strategy & Solution 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,018 F4 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2018. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 01:46 UTC | Cigna Group CI · Entity 550 | Tax withholdingCommon Stock, $.01 Par Value | 2,336 | $179.41 | $419,101.76 |
DisclosureSEC source: 0001225208-20-003954 · doc4.xml · nonDerivative · entry 3 Manders Matthew G · CIK 0001480601 · President, Strategy & Solution 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,987 F3 · shares: Represents shares withheld to satisfy tax obligations upon settlement of strategic performance shares. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 01:46 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 6,305 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003954 · doc4.xml · nonDerivative · entry 2 Manders Matthew G · CIK 0001480601 · President, Strategy & Solution 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,323 F2 · shares: The reported securities are shares of common stock received pursuant to the settlement of strategic performance shares for the 2017-2019 three-year performance period. The number of shares of common stock received was based upon actual performance against pre-established Company performance goals. Read SEC document |
| February 27, 2020 Filed Mar 3, 2020 01:46 UTC | Cigna Group CI · Entity 550 | Tax withholdingCommon Stock, $.01 Par Value | 548 | $185.76 | $101,796.48 |
DisclosureSEC source: 0001225208-20-003954 · doc4.xml · nonDerivative · entry 1 Manders Matthew G · CIK 0001480601 · President, Strategy & Solution 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,018 F1 · shares: Represents shares withheld to satisfy tax obligations upon vesting of restricted shares. Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 02:27 UTC | Cigna Group CI · Entity 550 | GrantEmployee Stock Option (Right to Buy) · Derivative | 18,586 | $0.00 Strike: $192.02 | $0.00 |
DisclosureSEC source: 0001225208-20-003810 · doc4.xml · derivative · entry 2 Manders Matthew G · CIK 0001480601 · President, Strategy & Solution 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,586 Underlying: Common Stock, $.01 Par Value · 18,586 shares Expires 2030-02-26 F2 · derivative.exercise_date: This option vests in three equal annual installments beginning February 26, 2021. Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 02:27 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 5,078 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003810 · doc4.xml · nonDerivative · entry 1 Manders Matthew G · CIK 0001480601 · President, Strategy & Solution 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,566 F1 · shares: These restricted shares vests in three equal annual installments beginning February 26, 2021. Read SEC document |
| November 12, 2019 Filed Nov 14, 2019 22:36 UTC | Cigna Group CI · Entity 550 | GiftCommon Stock, $.01 Par Value | 1,605 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-014503 · doc4.xml · nonDerivative · entry 1 Manders Matthew G · CIK 0001480601 · President, Strategy & Solution 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,488 Read SEC document |
| March 04, 2019 Filed Mar 7, 2019 00:49 UTC | Cigna Group CI · Entity 550 | SaleCommon Stock, $.01 Par Value | 4,758 | $178.98 | $851,586.84 |
DisclosureSEC source: 0001225208-19-004831 · doc4.xml · nonDerivative · entry 1 Manders Matthew G · CIK 0001480601 · President, Strategy & Solution 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,093 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2018. Read SEC document |
| March 01, 2019 Filed Mar 6, 2019 02:19 UTC | Cigna Group CI · Entity 550 | Tax withholdingCommon Stock, $.01 Par Value | 2,241 | $177.85 | $398,561.85 |
DisclosureSEC source: 0001225208-19-004743 · doc4.xml · nonDerivative · entry 2 Manders Matthew G · CIK 0001480601 · President, Strategy & Solution 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,851 F2 · shares: Represents shares withheld to satisfy tax obligations upon vesting. Read SEC document |
| March 01, 2019 Filed Mar 6, 2019 02:19 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 6,999 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-004743 · doc4.xml · nonDerivative · entry 1 Manders Matthew G · CIK 0001480601 · President, Strategy & Solution 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,092 F1 · shares: The reported securities are shares of common stock received pursuant to the settlement of strategic performance shares for the 2016-2018 three-year performance period. The number of shares of common stock received was based upon actual performance against pre-established Company performance goals. Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 01:22 UTC | Cigna Group CI · Entity 550 | GrantEmployee Stock Option (Right to Buy) · Derivative | 18,360 | $0.00 Strike: $183.44 | $0.00 |
DisclosureSEC source: 0001225208-19-004244 · doc4.xml · derivative · entry 2 Manders Matthew G · CIK 0001480601 · President, Strategy & Solution 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,360 Underlying: Common Stock, $.01 Par Value · 18,360 shares Expires 2029-02-27 F2 · derivative.exercise_date: This option vests in three equal annual installments beginning February 27, 2020. Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 01:22 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 5,316 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-004244 · doc4.xml · nonDerivative · entry 1 Manders Matthew G · CIK 0001480601 · President, Strategy & Solution 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,093 F1 · shares: These restricted shares vest in three equal annual installments beginning February 27, 2020. Read SEC document |
| December 20, 2018 Filed Dec 26, 2018 18:48 UTC | Cigna Holding Co CI · Entity 161580 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 28,038 | Not disclosed Strike: $149.14 | Not disclosed |
DisclosureSEC source: 0001567619-18-008665 · doc1.xml · derivative · entry 5 Manders Matthew G · CIK 0001480601 · President, Strategy & Solution 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.25 Par Value · 28,038 shares Expires 2027-02-28 F1 · kind: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2 · kind: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4 · price: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F3 · derivative.exercise_date: This option was fully vested and exercisable at the time of the Merger. Read SEC document |
| December 20, 2018 Filed Dec 26, 2018 18:48 UTC | Cigna Holding Co CI · Entity 161580 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 34,035 | Not disclosed Strike: $139.22 | Not disclosed |
DisclosureSEC source: 0001567619-18-008665 · doc1.xml · derivative · entry 4 Manders Matthew G · CIK 0001480601 · President, Strategy & Solution 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.25 Par Value · 34,035 shares Expires 2026-03-01 F1 · kind: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2 · kind: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4 · price: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F3 · derivative.exercise_date: This option was fully vested and exercisable at the time of the Merger. Read SEC document |
| December 20, 2018 Filed Dec 26, 2018 18:48 UTC | Cigna Holding Co CI · Entity 161580 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 30,229 | Not disclosed Strike: $120.90 | Not disclosed |
DisclosureSEC source: 0001567619-18-008665 · doc1.xml · derivative · entry 3 Manders Matthew G · CIK 0001480601 · President, Strategy & Solution 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.25 Par Value · 30,229 shares Expires 2025-02-25 F1 · kind: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2 · kind: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4 · price: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F3 · derivative.exercise_date: This option was fully vested and exercisable at the time of the Merger. Read SEC document |
| December 20, 2018 Filed Dec 26, 2018 18:48 UTC | Cigna Holding Co CI · Entity 161580 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 39,038 | Not disclosed Strike: $78.04 | Not disclosed |
DisclosureSEC source: 0001567619-18-008665 · doc1.xml · derivative · entry 2 Manders Matthew G · CIK 0001480601 · President, Strategy & Solution 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.25 Par Value · 39,038 shares Expires 2024-02-26 F1 · kind: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2 · kind: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4 · price: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F3 · derivative.exercise_date: This option was fully vested and exercisable at the time of the Merger. Read SEC document |
| December 20, 2018 Filed Dec 26, 2018 18:48 UTC | Cigna Holding Co CI · Entity 161580 | Disposition to issuerCommon Stock, $.25 Par Value | 37,777 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-008665 · doc1.xml · nonDerivative · entry 1 Manders Matthew G · CIK 0001480601 · President, Strategy & Solution 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2 · kind: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F5 · shares: Includes 2,352 restricted shares. F1 · price: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2 · price: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. Read SEC document |
| December 20, 2018 Filed Dec 27, 2018 00:15 UTC | Cigna Group CI · Entity 550 | GrantEmployee Stock Option (Right to Buy) · Derivative | 28,038 | Not disclosed Strike: $149.14 | Not disclosed |
DisclosureSEC source: 0001567619-18-008702 · doc1.xml · derivative · entry 5 Manders Matthew G · CIK 0001480601 · President, Strategy & Solution 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,038 Underlying: Common Stock, $0.01 Par Value · 28,038 shares Expires 2027-02-28 F1 · kind: Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna"), was acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F5 · price: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the effective time of the Merger (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F4 · derivative.exercise_date: This option was fully vested and exercisable at the time of the Merger. Read SEC document |
| December 20, 2018 Filed Dec 27, 2018 00:15 UTC | Cigna Group CI · Entity 550 | GrantEmployee Stock Option (Right to Buy) · Derivative | 34,035 | Not disclosed Strike: $139.22 | Not disclosed |
DisclosureSEC source: 0001567619-18-008702 · doc1.xml · derivative · entry 4 Manders Matthew G · CIK 0001480601 · President, Strategy & Solution 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,035 Underlying: Common Stock, $0.01 Par Value · 34,035 shares Expires 2026-03-01 F1 · kind: Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna"), was acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F5 · price: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the effective time of the Merger (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F4 · derivative.exercise_date: This option was fully vested and exercisable at the time of the Merger. Read SEC document |
| December 20, 2018 Filed Dec 27, 2018 00:15 UTC | Cigna Group CI · Entity 550 | GrantEmployee Stock Option (Right to Buy) · Derivative | 30,229 | Not disclosed Strike: $120.90 | Not disclosed |
DisclosureSEC source: 0001567619-18-008702 · doc1.xml · derivative · entry 3 Manders Matthew G · CIK 0001480601 · President, Strategy & Solution 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,229 Underlying: Common Stock, $0.01 Par Value · 30,229 shares Expires 2025-02-25 F1 · kind: Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna"), was acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F5 · price: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the effective time of the Merger (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F4 · derivative.exercise_date: This option was fully vested and exercisable at the time of the Merger. Read SEC document |
| December 20, 2018 Filed Dec 27, 2018 00:15 UTC | Cigna Group CI · Entity 550 | GrantEmployee Stock Option (Right to Buy) · Derivative | 39,038 | Not disclosed Strike: $78.04 | Not disclosed |
DisclosureSEC source: 0001567619-18-008702 · doc1.xml · derivative · entry 2 Manders Matthew G · CIK 0001480601 · President, Strategy & Solution 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,038 Underlying: Common Stock, $0.01 Par Value · 39,038 shares Expires 2024-02-26 F1 · kind: Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna"), was acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F5 · price: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the effective time of the Merger (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F4 · derivative.exercise_date: This option was fully vested and exercisable at the time of the Merger. Read SEC document |
| December 20, 2018 Filed Dec 27, 2018 00:15 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $0.01 Par Value | 37,777 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-008702 · doc1.xml · nonDerivative · entry 1 Manders Matthew G · CIK 0001480601 · President, Strategy & Solution 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,777 F1 · kind: Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna"), was acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F3 · shares: Includes 2,352 restricted shares acquired in the Merger. F1 · price: Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna"), was acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · price: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. Read SEC document |
| November 19, 2018 Filed Nov 20, 2018 19:27 UTC | Cigna Holding Co CI · Entity 161580 | GrantCommon Stock, $.25 Par Value | 2,352 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-015752 · doc4.xml · nonDerivative · entry 1 Manders Matthew G · CIK 0001480601 · President, Strategy & Solution 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,777 Read SEC document |
| July 24, 2017 Filed Jul 24, 2017 17:36 UTC | Cigna Holding Co CI · Entity 161580 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,596 | $0.00 Strike: $44.43 | $0.00 |
DisclosureSEC source: 0001225208-17-012827 · doc4.xml · derivative · entry 8 Manders Matthew G · CIK 0001480601 · Pres. Gov't & Ind Prog & Group 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.25 Par Value · 5,596 shares Expires 2022-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2017. F4 · derivative.exercise_date: This option was granted on February 28, 2012. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document |
| July 24, 2017 Filed Jul 24, 2017 17:36 UTC | Cigna Holding Co CI · Entity 161580 | Exercise / conversionCommon Stock, $.25 Par Value | 5,596 | $44.43 | $248,602.30 |
DisclosureSEC source: 0001225208-17-012827 · doc4.xml · nonDerivative · entry 5 Manders Matthew G · CIK 0001480601 · Pres. Gov't & Ind Prog & Group 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,395 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2017. Read SEC document |
| July 21, 2017 Filed Jul 24, 2017 17:36 UTC | Cigna Holding Co CI · Entity 161580 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 11,900 | $0.00 Strike: $44.43 | $0.00 |
DisclosureSEC source: 0001225208-17-012827 · doc4.xml · derivative · entry 7 Manders Matthew G · CIK 0001480601 · Pres. Gov't & Ind Prog & Group 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,596 Underlying: Common Stock, $.25 Par Value · 11,900 shares Expires 2022-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2017. F4 · derivative.exercise_date: This option was granted on February 28, 2012. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document |
| July 21, 2017 Filed Jul 24, 2017 17:36 UTC | Cigna Holding Co CI · Entity 161580 | SaleCommon Stock, $.25 Par Value | 11,900 | $175.01 | $2,082,665.41 |
DisclosureSEC source: 0001225208-17-012827 · doc4.xml · nonDerivative · entry 4 Manders Matthew G · CIK 0001480601 · Pres. Gov't & Ind Prog & Group 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,799 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2017. F3 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $175.00 to $175.06 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| July 21, 2017 Filed Jul 24, 2017 17:36 UTC | Cigna Holding Co CI · Entity 161580 | Exercise / conversionCommon Stock, $.25 Par Value | 11,900 | $44.43 | $528,657.50 |
DisclosureSEC source: 0001225208-17-012827 · doc4.xml · nonDerivative · entry 3 Manders Matthew G · CIK 0001480601 · Pres. Gov't & Ind Prog & Group 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,699 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2017. Read SEC document |
| July 20, 2017 Filed Jul 24, 2017 17:36 UTC | Cigna Holding Co CI · Entity 161580 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 12,457 | $0.00 Strike: $44.43 | $0.00 |
DisclosureSEC source: 0001225208-17-012827 · doc4.xml · derivative · entry 6 Manders Matthew G · CIK 0001480601 · Pres. Gov't & Ind Prog & Group 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,496 Underlying: Common Stock, $.25 Par Value · 12,457 shares Expires 2022-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2017. F4 · derivative.exercise_date: This option was granted on February 28, 2012. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document |
| July 20, 2017 Filed Jul 24, 2017 17:36 UTC | Cigna Holding Co CI · Entity 161580 | SaleCommon Stock, $.25 Par Value | 12,457 | $175.01 | $2,180,062.20 |
DisclosureSEC source: 0001225208-17-012827 · doc4.xml · nonDerivative · entry 2 Manders Matthew G · CIK 0001480601 · Pres. Gov't & Ind Prog & Group 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,799 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2017. F2 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $175.00 to $175.01 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| July 20, 2017 Filed Jul 24, 2017 17:36 UTC | Cigna Holding Co CI · Entity 161580 | Exercise / conversionCommon Stock, $.25 Par Value | 12,457 | $44.43 | $553,402.23 |
DisclosureSEC source: 0001225208-17-012827 · doc4.xml · nonDerivative · entry 1 Manders Matthew G · CIK 0001480601 · Pres. Gov't & Ind Prog & Group 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,256 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2017. Read SEC document |
| June 02, 2017 Filed Jun 6, 2017 17:44 UTC | Cigna Holding Co CI · Entity 161580 | SaleCommon Stock, $.25 Par Value | 6,000 | $165.00 | $990,000.00 |
DisclosureSEC source: 0001225208-17-010977 · doc4.xml · nonDerivative · entry 1 Manders Matthew G · CIK 0001480601 · Pres. Gov't & Ind Prog & Group 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,799 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.